Who
Julian S. Gangolli
Director
Company insider
Files Form 4 as: Director, Krystal Biotech; Director, Outlook Therapeutics; Director, Revance Therapeutics; President, North America, Gw Pharmaceuticals; CVP & Pres, North America, Allergan.
In numbers
- Trades disclosed
- 125
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $27.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 28 Nov 2011
- Last trade
- 14 Sep 2026
- Last filed
- 16 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 16 Sep 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,187 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —471 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,187 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —471 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,734 at $0.00 | filing |
| 30 Jun 2025filed 30 Jun 2025 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —15,000 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $110K30,106 at $3.65 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,636 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,169 at $0.00 | filing |
| 30 Jun 2024filed 1 Jul 2024 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | $455K20,000 at $22.75 | filing |
| 20 May 2024filed 22 May 2024 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.8M10,930 at $163.71 | filing |
| 20 May 2024filed 22 May 2024 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $1.2M7,090 at $164.34 | filing |
| 20 May 2024filed 22 May 2024 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $328K1,980 at $165.76 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,458 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeutics | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,441 at $0.00 | filing |
| 4 Oct 2023filed 6 Oct 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —370,282 at $0.00 | filing |
News
Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin SyndromeKRYS · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Julian S. Gangolli; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.